Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 40

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
3,888,660 592,262 5,980,922 Total2,350,117 3,920,811 1,194,617 7,465,545 The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.:Three Months Ended June 30,Nine Months Ended June 30,2025202420252024(in thousands)Research and development$6,898 $6,221 $21,008 $21,634 General and administrative5,095 8,490 20,242 27,350 Total$11,993 $14,711 $41,250 $48,984 Stock Option Awards            The following table presents a summary of the stock option activity for the nine months ended June 30, 2025:

18

SharesWeighted-AverageExercisePricePer ShareWeighted-AverageRemainingContractualTerm (Years)AggregateIntrinsicValueOutstanding at September 30, 20241,978,516$23.39 Granted—— Cancelled or expired(35,341)45.92 Exercised(458,552)7.55 Outstanding at June 30, 20251,484,623$27.75 3.5$5,750,674 Exercisable at June 30, 20251,484,623$27.75 3.5$5,750,674 The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended June 30, 2025 and 2024 was $0.3 million and $0.7 million, respectively. The total intrinsic value of the options exercised during the nine months ended June 30, 2025 and 2024 was $4.9 million and $3.8 million, respectively.For the three months ended June 30, 2025, there was no stock-based compensation expense related to stock options outstanding, while $0.4 million was recorded for the same period in 2024. Stock-based compensation expense related to stock options outstanding for the nine months ended June 30, 2025 and 2024, was $0.1 million and $2.5 million, respectively.As of June 30, 2025, the pre-tax compensation expense for all outstanding unvested stock